PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 15, 2025Journal of Molecular Medicine2 citationsOpen Access

Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration

View Full Paper
RSRui SatoKSK. SakaiSKSatoshi Kameshima

Key Points

  • This research aims to explore the effect of dapagliflozin on TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valve degeneration.
  • In vivo experiment in rats for assessing the effect of dapagliflozin on mitral valve degeneration.
  • Western blotting to determine protein expression levels and collagen gel contraction assay for contractile forces evaluation.
  • Histological staining to detect structural changes of the mitral valve.
  • Dapagliflozin inhibited TGF-β-induced Smad2/3 phosphorylation and increased alpha-smooth muscle actin expression.
  • Dapagliflozin increased AMPKα activity while gene knockdown of AMPKα inhibited its effects on Smad2 phosphorylation.
  • Dapagliflozin maintained cellular contractile force and suppressed mitral valve degeneration.

Abstract

Abstract Myxomatous mitral valve (MV) disease (MMVD) is a common cardiac condition in humans and dogs. Currently, no therapeutic agent is available for MMVD that can prevent MV degeneration. Transforming growth factor (TGF)-β-induced transdifferentiation of valvular interstitial cells (VICs) is a key process in MV degeneration. Dapagliflozin is used to treat type 2 diabetes, and it alleviates cardiac and renal fibrosis by inhibiting the TGF-β signaling pathway. In this study, we investigated the effect of dapagliflozin on TGF-β-induced transdifferentiation of VICs and MV degeneration in rats. Protein expression levels and contractile forces generated by VICs were determined using western blotting and a collagen gel contraction assay, respectively. Structural changes of the MV were detected using histological staining. Dapagliflozin inhibited TGF-β-induced Smad2/3 phosphorylation and increased alpha-smooth muscle actin expression and the cellular contractile force. In contrast, dapagliflozin increased the activity of adenosine monophosphate-activated protein kinase (AMPK)α. However, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, an AMPK activator, inhibited TGF-β-induced Smad2/3 phosphorylation. AMPKα gene knockdown impeded the inhibitory effect exerted by dapagliflozin on TGF-β-induced Smad2 phosphorylation. Additionally, dapagliflozin increased AMPKα phosphorylation and suppressed TGF-β-induced MV degeneration, alpha-smooth muscle actin expression, and Smad2/3 phosphorylation in isolated rat MV. To the best of our knowledge, this study is the first to demonstrate that dapagliflozin inhibits TGF-β-induced VIC differentiation and subsequent MV degeneration by suppressing Smad signaling via AMPK activation, suggesting that dapagliflozin is a potential novel therapeutic agent for MMVD. Key messages TGF-β-induced VIC differentiation leads to MV degeneration. DAPA, an SGLT2 inhibitor, suppresses the TGF-β signaling pathway. DAPA inhibits TGF-β-induced differentiation of rat VIC via AMPK activation. DAPA inhibits TGF-β-induced degeneration and signal transduction in isolated rat MV. DAPA suppresses MV degeneration by inhibiting VIC differentiation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sato et al. (2025) studied this question.

synapsesocial.com/papers/6941aaa70f5af7fd17df4aaahttps://doi.org/10.1007/s00109-025-02615-z
Ask AI
Helpful
Bookmark
Share
View Full Paper